Pharmaceutical companies Daiichi Sankyo and Ranbaxy announced plans to leverage Ranbaxy’s presence in Romania to market antibiotic Tavanic (levofloxacin), a synthetic antibacterial agent used to treat a broad range of infections.
The decision came after which Daiichi Sankyo and Sanofi-Aventis have agreed early this year to transfer the marketing rights of Tavanic in Romania and South Africa from Sanofi-Aventis to Ranbaxy.
Daiichi Sankyo worked with Sanofi-Aventis since 1993 for the manufacture and sales of levofloxacin covering Europe, Africa, Middle East, South America and part of Asia.
The transfer is expected to be effective in August 2010 for Romania. Commercialization of Tavanic by Sanofi-Aventis remains unchanged in the other territories.